Anti-CD20 mAbs were originally created to treat B cell proliferative diseases such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia, but they have since been used to treat autoimmune ...
The FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed cancer drug until September this year. Ofatumumab could ...
Novartis’ cancer therapy ofatumumab has moved closer to its second life as a treatment for multiple sclerosis, with a regulatory decision in the US due in June and in Europe in the first half of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback